StockMarketWire.com - AstraZeneca said its lupus drug had met its primary goal in a clinical trial.

The Phase III Tulip 2 trial for anifrolumab, a potential new medicine for the treatment of systemic lupus erythematosus (SLE), met its primary endpoint, achieving a 'statistically-significant and clinically-meaningful reduction in disease activity versus placebo, with both arms receiving standard of care,' the company said.

The reduction was measured using the British Isles Lupus Assessment Group based Composite Lupus Assessment (BICLA) at week 52. The BICLA required improvement in all organs with disease activity at baseline with no new flares.

'Systemic lupus erythematosus is a debilitating autoimmune disease, but only one new treatment has been approved in the last 60 years. These are important results and we will now review the full data set and explore pathways to bring this potential new treatment to patients,' said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D.




Story provided by StockMarketWire.com